ArticleRegenerative biomaterials2015
Bridging the lesion-engineering a permissive substrate for nerve regeneration.
Article in Regenerative biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Functional recovery after spinal cord injury through neuroprotection by lipoic acid-loaded hollow mesoporous Prussian blue nanozymes.Regenerative biomaterials · 2026Article
- A Review of the Potential Use of Antioxidants in Spinal Cord Injuries.Antioxidants (Basel, Switzerland) · 2025Review
- Biomaterials for neuroengineering: applications and challenges.Regenerative biomaterials · 2025Review
- Chitooligosaccharides accelarate myelin clearance by Wipi1 mediated Schwann cell autophagy promoting peripheral nerve regeneration.Regenerative biomaterials · 2025Article
- Locally controlled release of immunosuppressive promotes survival of transplanted adult spinal cord tissue.Regenerative biomaterials · 2023Article
- Mechanotransduction: Exploring New Therapeutic Avenues in Central Nervous System Pathology.Frontiers in neuroscience · 2022Review
- Integrated printed BDNF/collagen/chitosan scaffolds with low temperature extrusion 3D printer accelerated neural regeneration after spinal cord injury.Regenerative biomaterials · 2021Article
- Thermosensitive collagen/fibrinogen gels loaded with decorin suppress lesion site cavitation and promote functional recovery after spinal cord injury.Scientific reports · 2021Article
- Placenta mesenchymal stem cells differentiation toward neuronal-like cells on nanofibrous scaffold.BioImpacts : BI · 2020Article
- Hierarchically aligned fibrin nanofiber hydrogel accelerated axonal regrowth and locomotor function recovery in rat spinal cord injury.International journal of nanomedicine · 2018Article
- The combined strategy of mesenchymal stem cells and tissue-engineered scaffolds for spinal cord injury regeneration.Experimental and therapeutic medicine · 2017Article
- Ibuprofen-loaded fibrous patches-taming inhibition at the spinal cord injury site.Journal of materials science. Materials in medicine · 2017Article
- Drug-nanoencapsulated PLGA microspheres prepared by emulsion electrospray with controlled release behavior.Regenerative biomaterials · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomaterial-based strategies to restore connectivity after lesion at the spinal cord are focused on bridging the lesion and providing an favourable substrate and a path for axonal re-growth. Following spinal cord injury (SCI) a hostile environment for neuronal cell growth is established by the activation of multiple inhibitory mechanisms that hamper regeneration to occur. Implantable scaffolds can provide mechanical support and physical guidance for axon re-growth and, at the same time, contribute to alleviate the hostile environment by the in situ delivery of therapeutic molecules and/or relevant cells. Basic research on SCI has been contributing with the description of inhibitory mechanisms for regeneration as well as identifying drugs/molecules that can target inhibition. This knowledge is the background for the development of combined strategies with biomaterials. Additionally, scaffold design is significantly evolving. From the early simple hollow conduits, scaffolds with complex architectures that can modulate cell fate are currently being tested. A number of promising pre-clinical studies combining scaffolds, cells, drugs and/or nucleic acids are reported in the open literature. Overall, it is considered that to address the multi-factorial inhibitory environment of a SCI, a multifaceted therapeutic approach is imperative. The progress in the identification of molecules that target inhibition after SCI and its combination with scaffolds and/or cells are described and discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.